Evidence map›Paper›PMID 36045588›Full record

ArticleJournal of psychopharmacology (Oxford, England)2022

Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.

Crystal Zhou, David J Nutt, Simon Jc Davies

Open access · hybridAbstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. The pharmacology underlying the unique antipsychotic efficacy of clozapine.Journal of psychopharmacology (Oxford, England) · 2025
    Review
  3. Article
  4. Article
  5. How pharmacology can aid in the diagnosis of mental disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Crystal ZhouGeriatric Psychiatry Division, Centre for Addiction and Mental Health/University of Toronto, Toronto, ON, Canada.
David J NuttNeuropsychopharmacology Unit, Division of Brain Sciences, Imperial College London, London, UK.
Simon Jc DaviesGeriatric Psychiatry Division, Centre for Addiction and Mental Health/University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0095-5993
Centre for Addiction and Mental Health · CAImperial College London · GBIsland Health · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drugs used to treat psychotic disorders ('antipsychotics') have been widely used in psychiatry since the introduction of chlorpromazine in the mid-1950s. The categorization of these drugs evolved in a piecemeal way, relying initially on grouping by chemical structure (e.g. phenothiazines, butyrophenones), then by epoch of introduction (e.g. first generation ('conventional') vs second generation ('atypical')). As psychopharmacological expertise has advanced, it has become possible to quantify affinities for each drug in this class for relevant receptors including dopamine D2, 5HT2A, 5HT2C, histamine H1 and others. However, until the recent emergence of a new generation of agents known collectively as dopamine D2 receptor partial agonists (e.g. aripiprazole, brexpiprazole and cariprazine), there had been little reference in drug classification to specific pharmacological properties. An overview of data on receptor affinities across multiple drugs and receptor types would permit categorization according to binding affinities and putative pharmacological mechanisms. In this paper, we have attempted to construct a 'subway map' of 32 drugs used for treatment of psychotic disorders. This design allows a visualization of both the historical classifications by structure and epoch of introduction, and of the binding affinities for key receptors based on appraisal of scientific literature. The map represents a step towards categorization by mechanism, allowing prescribers and patients to understand which drugs share common biological features and the extent to which drugs may have similarities and differences in their mechanisms. In addition, this approach may encourage more logical groupings of drugs to be used in systematic reviews and meta-analyses.

Indexed as

Antipsychotic AgentsPsychotic DisordersRailroadsAripiprazoleButyrophenonesChlorpromazineDopamineDopamine AgonistsHistamineHumansReceptors, Dopamine D2Systematic Reviews as TopicAntipsychotic AgentsAripiprazoleButyrophenonesChlorpromazineDopamineDopamine AgonistsHistamineReceptors, Dopamine D2Antipsychoticsclassificationdopaminedrugs for psychosispsychopharmacology

Identifiers

PMID36045588
PMCPMC9516596
OpenAlexW4294127798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.